OBJECTIVE: To quantify clinical conditions and laboratory values associated with moderate to marked polyclonal gammopathy. PATIENTS AND METHODS: Patient characteristics, laboratory correlates, evolving disease states, and survival of all patients seen at the Mayo Clinic, Rochester, Minn, during 1991 with a polyclonal gamma globulin level of 3.0 g/dL or higher were reviewed in this retrospective cohort study. RESULTS: One hundred forty-eight patients were identified (median age, 58 years; 59% female). In 130 patients (88%), only 1 diagnosis was identified. Liver disease was the most common single disease association in 79 (61%) of 130 patients, followed by connective tissue diseases in 28 (22%), chronic infections in 8 (6%), hematologic disorders in 6 (5%), and nonhematologic malignancies in 4 (3%). No difference in gamma globulin levels existed between groups. With a median follow-up of 67 months, 90 (63%) of 143 patients for whom follow-up was available were alive. By multivariate analysis, age, albumin concentration, disease group, and platelet count were predictive of survival. No patient developed myeloma or a clonal plasmaproliferative disorder. CONCLUSION: Moderate to marked polyclonal gammopathy may reflect an underlying condition: liver disease, connective tissue disease, hematologic disorder, infection, or malignancy.
OBJECTIVE: To quantify clinical conditions and laboratory values associated with moderate to marked polyclonal gammopathy. PATIENTS AND METHODS: Patient characteristics, laboratory correlates, evolving disease states, and survival of all patients seen at the Mayo Clinic, Rochester, Minn, during 1991 with a polyclonal gamma globulin level of 3.0 g/dL or higher were reviewed in this retrospective cohort study. RESULTS: One hundred forty-eight patients were identified (median age, 58 years; 59% female). In 130 patients (88%), only 1 diagnosis was identified. Liver disease was the most common single disease association in 79 (61%) of 130 patients, followed by connective tissue diseases in 28 (22%), chronic infections in 8 (6%), hematologic disorders in 6 (5%), and nonhematologic malignancies in 4 (3%). No difference in gamma globulin levels existed between groups. With a median follow-up of 67 months, 90 (63%) of 143 patients for whom follow-up was available were alive. By multivariate analysis, age, albumin concentration, disease group, and platelet count were predictive of survival. No patient developed myeloma or a clonal plasmaproliferative disorder. CONCLUSION: Moderate to marked polyclonal gammopathy may reflect an underlying condition: liver disease, connective tissue disease, hematologic disorder, infection, or malignancy.
Authors: Francis Buadi; Ann W Hsing; Jerry A Katzmann; Ruth M Pfeiffer; Adam Waxman; Edward D Yeboah; Richard B Biritwum; Yao Tettey; Andrew Adjei; Lisa W Chu; Angelo DeMarzo; George J Netto; Angela Dispenzieri; Robert A Kyle; S Vincent Rajkumar; Ola Landgren Journal: Am J Hematol Date: 2011-06-14 Impact factor: 10.047
Authors: Rajesh K Grover; Xueyong Zhu; Travis Nieusma; Teresa Jones; Isabel Boreo; Amanda S MacLeod; Adam Mark; Sherry Niessen; Helen J Kim; Leopold Kong; Nacyra Assad-Garcia; Keehwan Kwon; Marta Chesi; Vaughn V Smider; Daniel R Salomon; Diane F Jelinek; Robert A Kyle; Richard B Pyles; John I Glass; Andrew B Ward; Ian A Wilson; Richard A Lerner Journal: Science Date: 2014-02-07 Impact factor: 47.728
Authors: A Gonzalez-Quintela; R Alende; F Gude; J Campos; J Rey; L M Meijide; C Fernandez-Merino; C Vidal Journal: Clin Exp Immunol Date: 2007-11-15 Impact factor: 4.330
Authors: Moayad Mustafa Hejazi; Ala Osman Bacha; Mohammed Kaleemuddin; Fahad A Al-Abassi; Abdulbasit I Al-Alsieni; Imran Kazmi; Firoz Anwar Journal: Mol Cell Biochem Date: 2017-12-16 Impact factor: 3.396